Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
Stocks that would benefit from a federal infrastructure spending program fell after President Trump ended a meeting on infrastructure spending with Democratic leaders.Market Insiderread more
Despite the president's claim that "you can't investigate and legislate simultaneously," certain must-pass pieces of legislation, including a debt ceiling hike, will...Politicsread more
A slew of retail earnings the past two weeks makes it clear that while Americans continue to shop, they aren't ringing registers at department stores.Retailread more
Amazon shareholders demanded the company to take action on a number of different issues during its annual shareholder meeting on Wednesday.Technologyread more
Talk about 5G is everywhere right now, from the trade-war with China to the ban on Huawei. Here's what 5G is and why it matters.Technologyread more
Controversial lawyer Michael Avenatti was indicted on charges of trying to extort athletic shoe giant Nike out of tens of millions of dollars by threatening to go public with...Politicsread more
Americans in certain areas of the country have significantly higher average credit scores than others. Experian's annual State of Credit report shows the average score in each...Spendread more
The president abruptly walked out of a meeting Wednesday, saying he would not negotiate with Democrats while they continue to investigate him.Politicsread more
More voters in five key industrial states disapprove than approve of Trump's handling of trade — 56% to 41%, according to a report.Politicsread more
Ireland's privacy watchdog, which leads supervision of Google in the EU, launched an inquiry into the firm's online advertising practices.Technologyread more
Walgreens Boots Alliance shareholders have instructed the company to explain how it's monitoring and managing risks related to the opioid crisis, according to preliminary results announced Friday at Walgreens' annual shareholders meeting.
The measure requires Walgreens to prepare a report by June 30 detailing any changes the company has made to its corporate governance since 2012 in response to the opioid crisis. Investors want more specifics, including how Walgreens' board oversees opioid-related programs and whether executive bonuses consider any opioid-related objectives like promoting ethical conduct.
Investors for Opioid Accountability, a coalition that includes state treasurers, comptrollers, asset managers, labor funds and faith-based groups, submitted the proposal. It has filed similar ones with nearly a dozen companies, including drug distributors AmerisourceBergen and Cardinal Health and drug companies Johnson & Johnson and Pfizer.
Walgreens' board opposed the proposal, saying it already discloses how it's handling the issue. Preliminary results showed shareholders voted in favor of the measure, though the company said final results will be released in a filing with the Securities and Exchange Commission. CEO Stefano Pessina is Walgreens' largest shareholder, holding about 15 percent of the company's stock, according to FactSet.
Drugmakers, distributors and pharmacies have all come under scrutiny for their role in the crisis that has killed scores of Americans. Lax prescribing and monitoring of prescription painkillers is widely seen as fueling opioid addiction. Now these companies face lawsuits from thousands of state and local governments.
Two influential proxy advisory firms, Glass Lewis and Institutional Shareholder Services, recommended shareholders vote in favor of the proposal. In its analysis, ISS said despite a proliferation of lawsuits, subpoenas and investigations related to the opioid crisis, Walgreens "does not seem to have taken steps at the board level related specifically to managing risks stemming from the opioid epidemic."
Glass Lewis in its analysis said a "more thorough discussion is warranted at this time."
They cite the immediate financial and legal risks to the company, as well as the additional threats. Walgreens owns about one-fourth of AmerisourceBergen, which is also embroiled in opioid litigation.